Количественный прогностический мониторинг эффективности радиотерапии злокачественных опухолей
Диссертация
Применяющиеся в клинике рентгенологические, томографические, эндоскопические и другие методы позволяют получить ответ о реакции опухоли на терапевтическое воздействие лишь через некоторое время после курса лечения, когда оптимальное индивидуальное планирование уже исключено. Таким образом, терапевтическое воздействие на организм больного продолжают даже тогда, когда оно не приносит никакого… Читать ещё >
Содержание
- ГЛАВА 1. ОЦЕНКА ЭФФЕКТИВНОСТИ ЛУЧЕВОЙ ТЕРАПИИ ОПУХОЛЕЙ (ОБЗОР ЛИТЕРАТУРЫ).у
- 1. Л. Факторы резистентности опухолей
- 1. 2. Принципы прогнозирования реакции опухолей
- 1. 2. 1. Прогноз эффективности лечения на основании реакции 25 первичного опухолевого узла
- 1. 2. 2. Параметры кривых выживаемости для прогноза реакции опухоли
- 1. 2. 3. Измерение клеточной кинетики
- 1. 2. 4. Естественная потеря клеток
- 1. 2. 5. Гетерогенность клеточных популяций в опухолях
- 1. 3. Использование иммунологических маркеров и молекулярно — 37 генетических методов для оценки эффективности проводимой терапии
- 1. 4. Использование радиофармпрепаратов для диагностики и терапии
- 1. 5. Использование радиоактивных маркеров для оценки эффективности 50 лучевой терапии на основе клеточно — кинетических параметров
- 1. 5. 1. 3. Н-, 14С-, пС-тимидин
- 1. 5. 2. 32. Р
- 1. 6. 5-йод-2'-дезоксиуридин — радиоактивный маркер реакции опухоли на терапевтическое воздействие
- 1. 2. Принципы прогнозирования реакции опухолей
- 1. Л. Факторы резистентности опухолей
- 2. 1. Постановка экспериментов
- 2. 2. Экспериментальные животные и опухолевые модели
- 2. 3. Используемые радиоизотопные маркеры
- 2. 4. Облучение опухолей
- 2. 5. Радиометрия и дозиметрия
- 2. 6. Параметры изменения роста опухоли
- 2. 7. Включение ЙДУР в ДНК опухолевых клеток
- 2. 8. Методы оценки экспериментальных данных
- 3. 1. Выведение 5-йод-2'-дезоксиуридина из опухолевой и здоровой ткани
- 3. 2. Оценка уровня потери из опухоли радиоактивного 5-йод-2'-дезоксиуридина, включившегося в опухоль до облучения
- 3. 2. 1. Культура клеток HeLa
- 3. 2. 2. Меланома В
- 3. 3. Оценка уровня включения в опухоль радиоактивного 5-йод-2'-дезоксиуридина после облучения
- 3. 3. 1. Меланома В
- 3. 3. 2. Саркома
- 3. 4. Сравнительная кинетика выведения I -5-йод-2'-дезоксиуридина и 1311−5-йод-2'-дезоксиуридина при локальном лучевом воздействии на опухоли
- 4. 1. Сравнение выведения меченого йодида в форме Na+Fn 5-йод-2'-дезоксиуридина из зоны опухоли
- 4. 1. 1. Выведение меченого йодида
- 4. 1. 2. Выведение меченого 5-йод-2'-дезоксиуридина
- 4. 2. Количественная in vivo оценка включения 5-йод-2'-дезоксиуридина в ДНК опухолевых клеток
- 4. 3. Параметры включения 5-йод-2'-дезоксиуридина для in vivo оценки уровня синтеза ДНК опухолевых клеток
- 5. 1. Влияние облучения на параметры роста опухолей
- 5. 1. 1. Оценка параметров роста опухоли
- 5. 1. 2. Действие локального облучения на изменение параметров роста опухоли
- 5. 2. Взаимосвязь роста опухоли и параметров выведения
Список литературы
- Берштейн Л.М. Гормональный канцерогенез.— СПб.: Наука, 2000, с. 199.
- Вайнсон А.А., Кримкер В. М., Щебетенко Ю. Е. Количественная оценка лучевых реакций опухоли в клинике. Материалы 9-й конференции памяти Л. Г. Грея. Мед. радиология, 1982, N 3, с. 81−84.
- Гусев Н.Г., Машкович В. П., Вербицкий Б. В. Радиоактивные изотопы как гамма-излучатели. М.:Атомиздат, 1964, с. 100
- Дрейпер Н., Г.Смит. Прикладной регрессионный анализ. -М: Статистика, Москва, 1973, -391 с.
- Заикин П.Н., Моисеев В. Н. Устойчивый метод интерпретации данных изотопного анализа.- ЖВМ и МФ, 1978, т. 2, с. 487- 492.
- Зубовский Г. А., Габуния Р. И. Основы радионуклидной диагнрстики. -В: Клиническая рентгенорадиология, Москва, Медицина, 1985, т. 4, с. 6−59.
- Канаев С.В., Семиглазов В. Ф., Бугрова И. Л., Власов А. Н. Оценка эффективности адъювантной лучевой терапии в консервативном лечении ранних стадий рака молочной железы pTl-2NOMO. -Вопросы онкологии, 1998, т.44, № 4, с.414−421.
- Козин С.В., Винская Н. Н. Волошина Е.А. Количественная оценка эффективности лучевой терапии опухолей в эксперименте (материалы IX Греевской конференции). Мед. радиология, 1982, N 4, с. 83−91
- Козин С.В., Фурманчук А. В. Особенности кровоснабжения опухолей и их роль при лучевой терапии, гипертермии и гипергликемии.- Мед. радиология, 1985, N 12, с. 76−83.
- Козин С.И., Волошина Е. А. Пострадиационное нарушение кровоснабжения опухолей при полирадиомодификации для повышения эффективности лучевой терапии. Мед. радиология, 1986, N 8, с. 53−56.12.
- Кушлинский Н.Е., Герштейн Е. С. Современные возможности молекулярно-биохимических методов оценки биологического «поведения» рака молочной железы. Вестн. РАМН, 2001, N9, с. 65−70.
- Лакин Г. Ф. Биометрия. М.: Высшая школа, 1973, — 231с.
- ОкадаШ. Радиационная биохимия клетки. М.: Наука, 1974,-407с.
- Пелевина И.И., Саенко А. С., Глтлиб В. Я., Сынзыныс Б. И. Выживаемость облученных млекопитающих и репарация ДНК. М.:
- Энергоатомиздат, 1985, 120 с.
- Пелевина И.И., Афанасьев Г. Г., Готлиб В. Я. Клеточные факторы ре акции опухолей на облучение и химиотерапевтические воздействия. М.: Наука, 1978, — 304 с.
- Пелевина И.И., Тимчева К. В. Клоногенные клетки в опухолях и их реакция на облучение и химиотерапевтические агенты.- Мед. радиология, 1981, с. 55- 60.
- Пискунов Н.С. Дифференциальное и интегральное исчисления. М.: Наука, 1965, т.1, с.129−134.
- Портной С.М. Возможности диагностики, прогнозирования течения и коррекция лечения рака молочной железы с помощью внутритканевого радиофосфорного исследования.- Автореф. канд. дис.- М.: ОНЦ РАМН, 1992, 48 с.
- Радиобиологические основы лучевой терапии (доклады проблемной комиссии «Радиобиология» 18−18 мая 1985 г.). Тбилиси, 1985. — 78 с.
- Рябухин Ю.С., Севастьянов А. И., Спрышкова Р. А. Влияние рентгеновского излучения на кинетику 5-йод-2'-дезоксиуридина в опухоли. -Мед. радиология, 1986, N 9, с. 35- 39.
- Соколов С.Н., Силин И. Н. Нахождение минимумов функционалов методом линеаризации. Препринт ОИЯИ — Дубна, 1961, Д-810.
- Спрышкова Р.А., Севастьянов А. И., Найденов М. Г. 125−1-йоддезоксиуридин в реакции экспериментальных опухолей на облучение.
- Мед. радиология, 1986, N 9, с. 40−45.
- Франкфурт О.С. Клеточный цикл в опухолях. М.: Медицина, 1975, -с. 172 .
- Хансон К.П., Комар В. Е. Молекулярные механизмы радиационной гибели клеток. М.: Энергоатомиздат, 1985, — 227 с.
- Хмелевский Е.В., Харченко В. П. Особенности лучевой терапии гормонзависимого рака молочной железы. Вопросы онкологии, 2003, т. 49, № 6., с. 711−715.
- Чан Тик Кань, Афанасьев Г. Г., Пелевина И. И. Клоногенная способноть клеток солидных опухолей NKLy/LL мышей и ее изменение при облучении. -М: Рад. онкология, 1978, т. 18, N 5, с.702−707.
- Эммануэль Н. М. Кинетика экспериментальных опухолевых процессов. -М: Наука, Москва, 1977, 416 с.
- Ярмоненко С.П., Вайнсон А. А. Радиобиология человека и животных. -М.: Высшая школа, 2004, 549 с.
- Ярмоненко С.П., Вайнсон А. А., Магдон Э. Кислородный эффект в лучевой терапии опухолей. М.: Медицина, 1980, — 247 с.
- Abe Y., Fukuda Н., Ishiwata К., et al. Studies oni'5 18i'0F-labeled pyrimidines. Tumor uptakes of 18-F-5-fluorouracil, 18-F-5-fluorouridine and 18-F-5-fluorodeoxyuridine in animals. Eur. J. Nucl. Med., 1983, v.8, pp.258−261.
- Agnarsson B.J., Bjomdottir I et al. Inherited BRCA 2 mutation associated with high grade breast cancer. Breast Cancer Res. Treat, 1998, 47: 121−7.
- Alavi JB., Alavi A., Goldberg HI., et al. Sequential computerized tomography and positron emission tomography studies in a patient with malignant glioma. Nucl. Med. Commun., 1987, v. 8, pp. 457- 568.
- Albaum H., Goldfeder A., Eisler L. Incorporation and Turnover of Radiophsphorus in Mouse Mammary Tomors (dbrB and C3H). Cancer Res., 1952, v. 12, N 3, pp. 188−191.
- Allaudeen H. S. Distinctive properties of DNA polymerases induced by herpes simplex virus type-1 and Epstein-Barr virus. Antiviral Research, February 1985, v.5, Issue l, pp. 1−12.
- Amorino G., Freeman M., Choy H. Enhancement of radiation effects in vitro by the estrogen metabolite 2-methoxyestradiot. Radiat. Res., 2000, v. 153, pp. 384 391.
- Ayata M., Yamane Т., Okamoto S., Kitamura Y. and Matsumoto K. Effect of long term androgen removal on androgen-induced proliferation of seminal vesicle cells in adult mice. -Journal of Steroid Biochemistry, October 1987, v. 28, Issue 4, pp. 399−403.
- Bader John P. Metabolic requirements for infection by rous sarcoma virus: III. The synthesis on viral DNA. Virology, May 1972, v. 48, Issue 2, pp. 485−493.
- Bagshawe К., Sharma S., Southall P. Selective uptake of toxic nucleoside (125-IUDR) by resistant cancer.- Br.J.Radiol, 1991, v.64, pp. 37 44.
- Bapat Ashok R., Daron Harlow H. and Aull John L. The photoinactivation of thymidylate synthase by 5-iodo-2'-deoxyuridylate. Biochimica et Biophysica Acta (BBA) — Protein Structure and Molecular Enzymology, 9 October 1984, v. 790, Issue 1, pp. 31−35.
- Barnum C.R., Huseby R.A., Vermud H. A time stady of the incorporation of radiophosphorus into the nucleic acids and other compounds of a transplanted mouse mammary carcinoma. Cancer Research, 1953, v.13, N 12, pp. 880−889.
- Bartelink Harry, Begg Adrian, Martin Jose Coco, Mariska van Dijk, Laura van’t Veer, et al. Towards prediction and modulation of treatment response. -Radiotherapy and Oncology, 1 January 1999, v. 50, Issue 1, pp. 1−11.
- Beatty J., Biggs P. J., Gall K., Okunieff P., Pardo F. S., Harte K. J., Dalterio M. J. and Sliski A. P. A new miniature x-ray device for interstitial radiosurgery: dosimetry. Med. Phys., 1996, v. 23, pp. 53−62.
- Begg A.C. Analysis of growth delay data: potential pitfalls. Brit.J.Cancer. 1980, v.41, Suppl, IV, pp. 93 — 96.
- Begg A.C. Cell loss from several types of solid murine tumour: comparison of I-125.-iododeoxyuridine and tritiated thimidine methods.- Cell Tissue Kinet. 1977, v. 10, pp. 409 416.
- Benda P., Lightbody J., Sato G., et al. Differentiated rat glial cell strain in tissue culture.- Science., 1968, v. 161, pp. 370 371.
- Berns P.M.J.J., Klij Klifn J.G.M., Van Staveren I.L., et al. Prevalence of amplification of the oncogenesis c-myc, HER2/ neu and int-2 in one thousand human breast tumors: correlation with steroid receptors. Europ. J. Cancer., v.28, pp. 697−700.
- Biggs D. S. and Thomson E. S. Radiation properties of a miniature x-raydevice for radiosurgery. Br. J. Radiol., 1996, v. 69, pp. 544−547.
- Biron Karen K. and Elion G. B. Effect of acyclovir combined with other antiherpetic agents on varicella zoster virus in vitro. The American Journal of Medicine, 20 July 1982, v. 73, Issue 1, Part 1, pp. 54−57.
- Bissonnette J. P. and Schreiner J. L. A comparison of semiempirical models for generating tungsten target x-ray spectra. Med. Phys., 1992, v. 19, pp. 579−582
- Boone J. M. The three parameter equivalent spectra as an index of beam quality. Med. Phys., 1988, v. 15, pp. 304−310
- Borisov G. Neutron dosimetry by means of Prompt gamma-ray spectrometry.-Atomn.Energ., 1986, v. 60, pp. 341−344.
- Borisov G., Komkov M., Kuzmichov V., et al. Equipment for NAA on reactor.- Atomn. Energ., 1986, v. 60, pp. 186−190.
- Bosiljanoff P., Porshen W., Piepenbring W. et al. In vivo untersuchungen uber die relative strahlenempfindlichke it hypoxischer tumorsellend.-Shtrahlentherapie 153, 1977, N3, pp. 178−189.
- Brotolli M., Maggiora P., Capello D. et al. Hormonal control of growth factor receptor expression. -Basis for Cancer Management, Eds. LCastagnetta, I.Nenci. H.L.Bradlow. New York: Academy of Sciences, 1996, pp. 336−345.
- Browne E. and Firestone R. B. Table of Radioactive Isotopes 1986 (New York: Wiley).
- Bruno S., Poster D., Bono V., Mac Donald J., Kubota T. High-dose thymidine in clinical oncology. Cancer Treat. Rep., 1981, v.65, pp. 57- 63.
- Burke W. et al. Recommendations for follow-up care of individuals with the inherited predisposition to cancer. 11. BRCA 1 and BRCA2. JAMA 277, 1997, pp. 997−1003.
- Byrd Daniel M. and Prusoff William H. The effect of 5-Iodouracil on the growth and biosynthetic processes of bacteriophage T4td8 in the absence of light. -Chemico-Biological Interactions, February 1976, v. 12, Issue 2, pp. 197−210.
- Calabresi P., Cardoso S., Finch S. et al. Initial clinical studies with 5-iodo2'-deoxyuridine.-Cancer Res., 1961, v.21,pp. 550−559.
- Crusso A., Gianni 1., Kinsella T. Pharmacological evaluation of intravenous delivery of 5-bromodeoxyuridine to patients with brain tumors. -Cancer Res., 1984, v.44, pp. 1702−1705.
- Cathy S. Cutler, Jason S. Lewis, Carolyn J. Anderson. Utilization of metabolic, transport and receptor-mediated process to deliver agents for cancer diagnosis. -Advanced Drug Delivery Reviews, 5 april 1999, v.37, pp. 189−211
- Chapman J.D., Bradley Jeffrey D., Eary Janet F., et al. Molecular (functional) imaging for radiotherapy applications: an RTOG symposium, Int J of Radiation Oncology, Biology, Physics, v.55, 1 February 2003, pp.294−301
- Chen Mei-Ru, Hsu Tsuey-Ying, Chen Jen-Yang and Yang Czau-Siung.
- Molecular characterization of a cDNA clone encoding the Epstein-Barr virus (EBV) DNase. -Journal of Virological Methods, August 1990, v. 29, Issue 2, pp. 127−141.
- Christman D., Crawford EJ., Friedkin M., et al. Detection of DNA synthesis in intact organisms with positron-emitting methil-llC. thimidine. -Proc. Natl. Acad. Sci., USA, 1972, v.69, pp. 988−992.
- Ciardiello F., Tortora G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin. Cancer Res., 2001, v. 7(10), pp. 2958−2970.
- Clifton K.H., Yatvin M.B. Cell population growth and cell loss in the MTG-B mouse mammary carsinoma. Cancer Res., 1970, v.30, pp.658−664.
- Commerford S. L. and Joel D. D. Iododeoxyuridine administered to mice is de-iodinated and incorporated into DNA primarily as thymidylate. Biochemical and Biophysical Research Communications, 15 January 1979, v. 86, Issue 1, pp. 112−118.
- Commerford S.L. Biological stability of IURD labeled with 125−1 after incorporation intu the DNA of the mouse. Nature, 1965, v.206, pp. 949−950.
- Conti P., Grossman S., Wilson A., et al. Laboratory and clinical imaging studies of primary brain tumours using llC-thymidine positron emissiontomography (PET) Abstract. Proc. Ann. Meet. Am. Soc.Clin. Oncol., 1990, v.9, P. 357.
- Couch F.J., et al. BRCA 1 mutations in women attending clinics that evaluate the risk of breast cancer. N. Engl. J. Med. 336: 1409−1415, 1997.
- DeGroot LJ. Kinetic analysis of iodine metabolism. J.Clin.Endocrinol., 1966, v.26, p. 149.
- Denecamp J., Kallmar R.F. In vitro and in vivo labelling of animal tumours with tritiated thimidine. Cell Tissue Kinetics, 1973, v.6, pp. 217−221
- Denecamp J., Stewart F.A. Evidence for reduced repair capaciti in mouse tumoure relative to normal tissues. -Int.J. Radiat. Oncol. Biol.Phys., 1979, v.5, pp. 2003−2009.
- Dethlefsen L.A. Incorporation 125-I-labeled 5-iodo-2'-deoxyuridine into the DNA of mouse mammary tomors. -New-York, SpringerVerlag, 1969, pp. 186−201.
- Dethlefsen L.A. Reutilization of 131-I-5-Iodo-2'-deoxyuridine as compared to 3-H-thimidine in mouse duodenum and mammary tumour. -J.Natl.Cancer Inst., 1970, v.44, pp. 827- 840.
- Dexter D.L., Calabresi P. Intraneoplastic diversity. Biochim. et Biophys. Acta 1982. v. 695, pp. 97−112.
- Dinsmore M, Harte K. J., Sliski A. P., Smith D. 0, Nomilos P. M., et al. A new miniature x-ray source for interstitial radiosurgery: device description. Med. Phys., 1996, v. 23, pp. 45−52.
- Djordjevic В., Szybalski W. Genetics of human cells lines III Incorporation of5. bromo and 5-iododeoxyuridine into the deoxyribonucleic acid of human cells and its effect on radiation sensitivity. -J. Exp.Med., 1960, v. l 12, p.509.
- Domin Barbara A., Mahony William B. and Zimmerman Thomas P. Desciclovir permeation of the human erythrocyte membrane by nonfacilitated diffusion. Biochemical Pharmacology, 21 June 1991, v. 42, Issue 1, pp. 147−152.
- Dubravsky N.B., Maor M.N., Withers H.R. Radiation-induced inhibition of thymidine incorporation in vivo as a measure of the initial slope and RBE nO. Int.J.Radiaat. Oncol.Biol.Phys., 1985, v. ll, N8, pp.1513−1517.
- Duffy M.J. Biochemical markers in breast cancer: which ones are clinically useful? Clin. Biochem., 2001, v. 34(5), pp. 347−352.
- Elequin F. Muggia F.M. Ghossen N.A. Correlation between in vitro labeling indicer and tumour regression following radiotherapy. Int. J. Radiat. Oncol. Biol. Phys., 1978, v. 4, N3, pp. 207−213
- Ensminger W., Rosowsky A., Raso V., et al. A clinical-pharmacological evaluation of hepatic arterial infusions of 5-fluoro-2'- deoxyuridine and 5-fluorouracil.- Cancer Res., 1978, v.38, pp.3784−3792.
- Epstein A. H., Cook J. A., Goffrnan T. and Glatstein E. Tumour radiosensitization with the halogenated pyrimidines 5/-bromo- and 5-iododeoxyuridine. Br. J. Radio 1., 1992, (suppI24), pp. 209−214
- Fischer Paul H., Fang Tzann-Tarn, Lin Tai-Shun, Hampton Alexander and Bruggink Joan. Structure-activity analysis of antagonism of the feedback inhibition of thymidine kinase. Biochemical Pharmacology, 1 April 1988, v. 37, Issue 7, pp. 1293−1298.
- Fischer Paul H., Vazquez-Padua Miguel A. and Reznikoff Catherine A. Perturbation of thymidine kinase regulation: A novel chemotherapeutic approach. -Advances in Enzyme Regulation, 1986, v. 25, pp. 21−34.
- Ford D, Easton D, Stratton M et al. Genetic heterogeneity and penetrance analysis of the BRCA 1 and BRCA 2 genes in breast cancer families. Am J Hum Genet, 1998, 62, pp. 676−689.
- Freidman L.S. et al Mutation analysis of BRCA 1 and BRCA 2 in a male breast cancer Population.- Am. J. Hum Genet., 1997, 60, pp. 313−319.
- Gasparini G. Clinical significance of determination of surrogate markers of angiogenesis in breast cancer. Crit. Rev. Oncol. Hematol., 2001, v. 37(2), pp. 97 114.
- Gerweck L.E. Hyperthermia in cancer therapy: the biological basis andunresolved questions. Cancer Res., 1985, v.45, N8, pp.253−262.
- Gitlin D., Commerford S.L., Amsterdam E., Hughes W.L. X-rays affect the incorporation of 5-IUDR into DNA. Science, 1961, v.133, p. 1074
- Goethals Laurence, Debucquoy Annelies, Perneel Christiaan, Geboes Karel, Ectors Nadine, et al. Haustermans Hypoxia in human colorectal adenocarcinoma: Comparison between extrinsic and potential intrinsic hypoxia markers.
- Gorski B, Debniak T, Masojc В et al. Gennline 657 de 15 mutation in the NBSS gene in breast cancer patients.- BCLC Familial Cancer, 2005, 2. pp. 214−5.
- Gorthals P., Lodewyckx W., Eijkeren M. Van, Dams R. Radioiodination of 2'-deoxyuridine: Preparation and preliminary evaluation in tumour-bearing rats, v.45, No 2, pp. 149−153
- Gutierrez Crisanto. Excision repair of uracil in higher plant cells: Uracil-DNA glycosylase and sister-chromatid exchanges. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis, November 1987, v. 181, Issue 1, pp. 111−126.
- Hackel P.O., Zwick E., Prenzel N., Ullrich A. Epidermal growth factor receptors: critical mediators of multiple receptor pathways. Current Opinion on Cell Biology, 1999, v. 11, pp. 184−189.
- Hall E. J. Radiobiology for the Radiologist, 1988, 3rd edn (Philadelphia, PA: Lippincott).
- Hamilton A., Piccart M. The contribution of molecular markers to the prediction of response in the treatment of breast cancer: a review of the literature on HER-2, p53 and BCL-2. -Ann. Oncol., 2000, v. 11(6), pp. 647−663.
- Hampton E., Eidinoff M. Administration of 5-iododeoxyuridine-I-131 in the mouse and rat. Cancer Res., 1961, v.21, pp. 345−352
- Hayward J.L., at al. 2C-radiolabelled yhymidine: a poitential tracer for measurement of liver regeneration by PET Abstract. J Nucl Med., 1989, v. 30, pp. 30−929.
- Harari P., Huang S. Head and neck cancer as a clinical model for molecular targeting of therapy: Combining EGFR blockade with radiation. Int. Radiat. Oncol. Biol. Phys., 2001, v. 49, pp. 427−433.
- Haustermans Karin and Fowler Jack F. Is there a future for cell kinetic measurements using IdUrd or BdUrd? International Journal of Radiation Oncology, Biology, Physics, 1 February 2001, v. 49, Issue 2, pp. 505−511.
- Herdewijn P., Kerremans L., Snoeck R., Van Aerschot A., Esmans E. and De Clercq E. Synthesis and anti-herpes activity of 5-trifluorovinyl-2'-deoxyuridine. -Bioorganic & Medicinal Chemistry Letters, September 1992, v. 2, Issue 9, pp. 10 571 062.
- Hewitt H.B., Wilson C.W.A survival curve for mammalian leokemia cells irradiated in vivo (implications for the treatment of mouse leukemia dy whole body irradiation). -Brit., J Cancer, 1959, v. 13, pp. 69−75.
- HoferK.G. Hughes W.L. Incorporation of 125-Ilododeoxyuridine into the DNA of L1210 leukemia cells during tumour development. Cancer Res., 1970, v.30, pp. 236−243.
- Hofer K.G. Radiation effects on death and migration of tumour cells inmice. Radiat.Res., 1970, v.43, pp. 663−678.
- Hofer K.G. Hofer M. Kinetics of proliferation, migration and death of L1210 ascites cells. Cancer Res., 1971, v.31, pp. 402−408.
- Hofer K.G. Prensky W. Hughes W.L. Death and metastatic distribution of tumour cells in mice monitored with 125-I-IDUR. J.Natl.Cancer Inst., 1969, v.43, pp.763−773.
- Holt S., Croton R., Leinster S.J., et al. In vitro thymidin labelling index in primary operable breast cancer. Eur.J. Surg. Oncol., 1986, V.12, N 1, pp.53−57.
- Hoshino Т., Nagashima Т., Murovic J., et al. In situ cell kinetics studies on human neuroectodermal tumors with bromodeoxyuridine labeling. J.Neurosurg., 1986, v.64, pp. 453−459.
- Howell S., Chu В., Mendelsohn J., et al. Thymidine as a chemotherapeutic agent: pharmacologic, cytokinetic and biochemical studies in a patient with T-cell acute lymphocytic leukemia.-J.Natl.Cancer Inst., 1980, v.65, pp.277−284.
- Howell S., Ensminger W., Krishan A., Frei E. Thymidine rescue of high-dose methotrexate in humans. Cancer Res., 1978, v.38, pp.325−330.
- Hughes W.L., Commerford S.L., Gitlin D. DNA metabolism in vivo: l. Cell proliferation and death as measured by incorporation and elimination of IDUR.-Fed.Proc., 1964., v.23, pp. 640−648.
- Humm J. L. and Charlton D.E. Double strand breakage in DNA produced by the photoelectric interaction with incorporated 'cold' bromine. DNA Damage by Auger Emitters (London: Taylor and Francis). 1988, pp. 111−122.
- Humm J., Bagshawe K., Sharma S., Boxer G. Tissue dose estimates following the selective uptake of 5 -125IUDR and other radiolabeled thymidine precursors in resistant tumors.- Br.J.Radiol, 1991, v.64, pp.45−49.
- Johannson O, RanstamJ, Borg A., et at. Sunital of BRCA 1 breast and ovarian cancer in patients: apopulation- based study from southern Sweden. -J.C.Un Oncol., 1998, v.16: 1, pp. 397−404.
- Johannson O., Bendahl O. et al. Steroid receptors in hereditary breast carcinomas associated with BRCA 1 or BRCA 2 mutations or unknown susceptibility genes. Cancer, 1998, v. 83, pp. 310−319.
- Kaptain S., Tan L.K., Chen B. Her-2/neu and breast cancer. -Diagn. Mol. Pathol., 2001, v. 10(3), pp. 139−152.
- Karnas S. J., Awakumov N., Bouius D., Yu. E and Battista J. J. Early performance of a new miniature x-ray needle for high dose rate brachytherapy. -Med. Phys., 1998, v. 25, P. 1573.
- Kim В., Keenen S., Bodnar J., Sander E. Role of enzymatically catalyzed 5-iodo-5,6-dihydrouracil ring hydrolysis on the dehalogenation of 5-iodouracil.-J.Biol.Chem., 1976, v.251, pp. 6909−6914.
- Kinsella Т., Collins J., Rowland J., et al. Pharmacology and phase I/II study of continuous intravenous infusions of iododeoxyuridine and hyperfractionated radiotherapy in patients with glioblastoma multiforme. J.Clin.Oncol., 1988, v.6, pp. 871−879.
- Kit Saul, Ichimura Hiroshi and De Clercq Erik. Phosphorylation of nucleoside analogs by equine herpesvirus type 1 pyrimidine deoxyribonucleosidekinase. Antiviral Research, January 1987, v. 7, Issue 1, pp. 53−67.
- Kitamura Y., Uchida N., Odaguchi K., Yamaguchi K., Okamoto S. and Matsumoto K. Insignificance of pituitary for growth of androgen-dependent mouse mammary tumor. Journal of Steroid Biochemistry, March 1980, v. 13, Issue 3, pp. 333−337.
- Klecker Jr.R., Kinsella Т., Fine L., et al. Clinical pharmacology of 5-iodo-2'-deoxy uridine and 5-iodouracil and endogenous pyrimidine modulation.-Clin.Pharmacol.Ther., 1985, v.38, pp.45−51.
- Kriss J., Revesz L. The distribution and fate of bromodeoxyuridine and bromodeoxycytidine in the mouse and rat.- Cancer Res., 1962, v.22, pp.254−265.
- Kriss J., Maruyama, Y., Tung L., et al. The fate of 5-bromodeoxyuridine, 5-bromodeoxycytidine in man. Cancer Res., 1963, v.23, pp.260−268.
- Kruger R.C. Gitlin D. Commerford S.L. IdU as a trecer of DNA metabolism in vivo. Fed.Proc., 1960, v.19, p.307.
- Ku Katharine Y. and Goz Barry. 5-Iodo-2'-deoxyuridine inhibition of Dictyostelium discoideum differentiation and cyclic AMP phosphodiesterase activity. Biochemical Pharmacology, 1978, v. 27, Issue 11, pp. 1597−1601.
- Kufe D., Egan E., Posowsky A., et al. Thymidine arrest and synchrony ofcellular growth in vivo.- Cancer Treat.Rep., 1980, v.64, pp. 1307−1317.
- Kuroishi Т., Tominaga S., Morimoto Т., et al. Tumor Growth Rate and Prognosis of Breast Cancer Maihly Detected by Mass Screening. Jpn J. Cancer Res., 1990, v.81, N 5, pp. 454−462.
- Lakbani S, Sloane J, Gusterson В et al. A detailed analysis of the morfological features associated with breast cancer in patients harbouring mutations in BRCM and BRCA 2 predisposition genes. J. Nat. Cancer Inst., 1999, v. 90, pp. 1138−1145.
- Langen K.J., Roosen N., Kuwert Т., et al. Early effects of intra-arterial chemotherapy in patients with brain tumors studied with PET: preliminary results. Nucl. Med. Commun., 1989, v. 10, pp.779−790.
- Laster В. H., Thomlinson W. C. and Fairchild R. G. Photon activation of iododeoxyuridine: biological efficacy of Auger electrons. -Radiat. Res., 1993, v. 133, pp. 219−224
- Lawrence T. Davis, M., Maybaum J., Stetson P., Ensminger W. The dependence of halogenated pyrimidine incorporation and radiosensitization on the duration of drug exposure. Int.J.Radiet.Oncol.Biol.Phys., 1990, v.18, pp. 13 931 398.
- Lee D., Prensky W., Krause G., Hughes W. Blood thymidine level and iododeoxyuridine incorporation and reutilization in DNA in mice given longacting thimidine pellets. Cancer Res., 1976, v.36, pp. 4577- 4583.
- Lee S., Giovanella В., Stehin J, Effect of excess thymidine on the growth of human melanoma cells transplanted in thymus deficient nude mice. Cancer Lett., 1977, v.3, pp.209−214.
- Leith J.T. Unequal medification of the thermal survival responses of clonal human colon carcinoma cell lines by decreased pH. Int.J. Radiat.Biol., 1985, v.47, N 3, pp.267−273.
- Liaiv D, Marsb D, Li F. et al. Germ line mutations of the PTEN gene in Coulden disease, an in hereditary breast and thyroid cancer syndrom. Nat. Genet., 1997, v. 16: 64, P. 31.
- Linderholm В., Lindh В., Tavelin B. et al. p53 and vascular-endothelial-growth-factor (VEGF) expression predicts outcome in 833 patients with primary breast carcinoma. -Int. J. Cancer., 2000, v. 89(1), pp. 51−62.
- Little John B. Characteristics of radiation-induced neoplastic transformation in vitro. Leukemia Research, 1986, v. 10, Issue 7, pp, 719−725.
- Lliakis G., Kurtzman S. Keynote address: application of non-hypoxic cellsensitizers in radiobiology and radiotherapy: rationale and future prospects. Int. J. Radiat. Oncol. Biol. Phys., 1989, v. 16, pp. 1235−1241.
- Low-Beer B.V.A., Bell H.G., McCorcle H.J., et al. Measurment of Radioaktive Phosphorus in Breast Tumors in Situ: a Possible Diagnostic Procedure.
- Preliminary Report. Radiology, 1946, N 47, pp. 492 — 493. i
- Mahmood U., Devitt ML., Koheheril PG., et al. Quantitation of total metastatic tomor volume in the rat liverxorrelation of MR and histologic measurements.-J.MRI, 1992, v.2,pp.335−340.
- Mahony William В., Zimmerman Thomas P. An assay for inhibitors of nucleoside transport based upon the use of 5−125I.iodo-2'-deoxyuridine as permeant, Analytical Biochemistry, April 1986, v. 154, Issue 1, pp. 235−243.
- Mahony William В., Domin Barbara A. and Zimmerman Thomas P. Ganciclovir permeation of the human erythrocyte membrane. Biochemical Pharmacology, 15 January 1991, v. 41, Issue 2, pp. 263−271.
- Marcus J, Watson P, Page D et al. BRCA 2 hereditary breast cancer phenotype. -Breast Cancer Res Treat, 1997, v. 44, pp. 275−277.
- Mathias A., Fischer G., Prusoff W. Inhibition of the growth of mouse leukemia cells in culture by 5-iododeoxyuridine. Biochim. et Biophys.Acta, 1959, v.36, рр.560−561.
- Meyer J.S., Friedman E., McCrate M.M., Bauer W. Prediction of early course of breast carcinoma by thymidine labelling. Cancer, 1983, v.51, N 10, pp. 1879−1886.
- Meyer J.S., Province M. Proliferative index of breast carcinoma by thymidine labelling: prognostic power independent of stage, estrogen and progesterone receptors. Breast Cancer Res. Treat., 1988, N 12, pp. 191−204.
- Miller R. W., DeGraff M. S., Kinsella M. D. and Mitchell J. B. Evaluation of incorporated iododeoxyuridine cellular radiosensitization by photon activation therapy. Int. J. Radiat. Oncol. Biol. Phys., 1987, v. 13, pp. 1193−1197.
- Mineura K., Yasuda Т., Kowada M., Ogawa Т., ef al. Positron emission tomographic evaluation of radiochemotherapeutic effect on regional cerebral hemocirculation and metabolism in patients with gliomas.- J. Neuro Oncol., 1987, v.5, pp.277−285.
- Moghal N., Sternberg P. W. Multiple positive and negative regulators of signaling by the EGF-receptor. Current Opinion on Cell Biology, 1999, v. 11, pp. 190−196.
- Molnar P., Groothuis D., Blasberg R., et al. Regional thimidine transport and incorporation in experimental brain and subcultaneous tumors.-J. Neurochem., 1984, v.43, pp. 421−432.
- Naidenov M., Spryshkova R, Borisov G., Komkov M. Express method of quantity measurement of boron in native biological samples. Med. ref., 1986, Z.5, p. 1046.
- Nath R., Bongiorni P. and Rockwell S. Iododeoxyuridine radiosensitization by low- and high-energy photons for brachytherapy dose rates. Radiat. Res., 1990, v.124, pp. 249−258.
- Nazerian К. Marelc’s disease lymphoma of chicken and its causative herpesvirus. Biochimica et Biophysica Acta (BBA) — Reviews on Cancer, 30 November 1979, v. 560, Issue 3, pp. 375−395.
- Nicholson R. L, Gee J.M., Harper M.E. EGFR and cancer prognosis. Europ. J. Cancer., 2001, v. 37, Suppl. 4, pp. 9−15.
- Nicolini Claudio. The principles and methods of cell sychronization in cancer chemotherapy. Biochimica et Biophysica Acta (BBA) — Reviews on Cancer, 12 October 1976, v. 458, Issue 3, pp. 243−282.
- Ogawa Т., Uemura K., Shishibo F., et al. Changes of cerebral blood flow, oxygen and glucose metabolism following radiochemotherapy of gliomas: a PET study. J. Comput. Assist. Tomogr., 1988, v. 12, pp. 290−297.
- Otto Michael J., Lee J. J. and Prusoff William H. Effects of nucleoside analogues on the expression of herpes simplex type 1-induced proteins. Antiviral Research, October 1982, v. 2, Issue 5, pp. 267−281.
- Painter R. B. and Young B. R. Repair replication induced by 3H incorporated into HeLa DNA. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis, February 1974, v. 22, Issue 2, pp. 203−206.
- Petereit Daniel G. and Kinsella Timothy J. An approach to radiosensitizingcervical cancer by use of chemical modulators of nucleoside metabolism. Seminars in Radiation Oncology, October 1997, v. 7, Issue 4, pp. 324−334.
- Pitha P. M., Pitha J. and Rowe W. P. Lack of requirement of reverse transcriptase function for the activation of murine leukemia virus by halogenated pyrimidines. Virology, February 1975, v. 63, Issue 2, pp. 568−572.
- Pitha Paula M., Rowe Wallace P. and Oxman Michael N. Effect of interferon on exogenous, endogenous, and chronic murine leukemia virus infection. -Virology, April 1976, v. 70, Issue 2, pp. 324−338.
- Porschen R., Porschen W., Muhlensiepen H. Cell ioss from viable and necrotic tumour regions measured by 125-I-UDR. Cell tissue kinet., 1983, v. 16, pp.549−556.
- Porschen W., Feinendegen L.E. In vivo-destimmung der zellverlustrate bei experimentaltumoren mit markiertem joddeoxyuridin. -Strahlentherapie, 1969, v.137, pp. 718−723.
- Porschen W., Feinendegen L.E. Biologische in vivo dosimetric von 15 NeV-neutronen bei normalen und tumorzellen-zellmarkierung mit iod-125-desoxyuridin.-Strahlentherapie, 1973, v. 145, N1, pp.27−38.
- Prichard Mark N., Prichard Lynn E. and Shipman Charles. Inhibitors of thymidylate synthase and dihydrofolate reductase potentiate the antiviral effect of acyclovir. Antiviral Research, March 1993, v. 20, Issue 3, pp. 249−259.
- Prusoff W. Incorporation of iododeoxyuridine, an analog of thymidine, into mammalian deoxyribonucleic acid. Fed. Proc., 1959, v. 18, P. 305
- Prusoff W., Jaffe J., Gunther H. Studies in the mouse of the pharmacology of 5-iododeoxyuridine, an analogue of thymidine. — Biochem. Pharmacol., 1960, v.3, pp. 110−121
- Prusoff W.H. Incorporation of iododeoxyuridine, an analog of thimidine, into mammalian deoxyribonucleic acid. -Fed.Proc., 1959, v. 18, p.305.
- Prusoff W.H. Synthesis and biological activiyies of iododeoxyuridine, an analog of thimidine. Biochim.Biophys.Acta, 1959, v.32, pp.295−296.
- Prusoff W.H., Jaffe J., Gunther H. Studies in the mouse of the pharmacology of 5-iododeoxyuridine, an analogue of thymidine. Biochem. Pharmacol., 1960, v.3, pp.110−121.
- Puck T.T., Marcus P. W. Action of X-rays on mammalian cells. Expt. Med, 1956, v. 103, pp. 653−666.
- Ritter Mark A. The radiotoxicity of iodine-125 in ataxia telangiectasia fibroblasts. Biochimica et Biophysica Acta (BBA) — Nucleic Acids and Protein Synthesis, 29 January 1981, v. 652, Issue 1, pp. 151−159.
- Rozental JM., Levine R.L., Dodkid JA. Glucose uptuke by gliomas after treatment. A positron emission tomographic stady. -Arch Neuml, 1989, v 46, pp.1302−1307.
- Ryabukhin Yu.S. The problem of individualized monitoring for tumour and normal tissue responses during radiation therapy. Strahlentherapie, 1984, v. 160, N11, pp.678−680.
- Rubin H. Experimental control of neoplastic progresion in cell populations: Foulds’rules revisited. Proc.Natl.Acad.Sci. USA 1994. v. 91, pp.6619−6623.
- Sastry K. S. R. Biological effects of the Auger emitter iodine-125: a review. -Report no 1 of AAPM Nuclear Medicine Task, Group No 6, Med. Phys., 1992, v. 19, pp. 1361−1369.
- Scott J. Karnast, Edward Yu. J. Optimal photon energies for IUdR K-edge radiosensitization with filtered x-ray and radioisotope sources Phys. Med. Biol., 1999, v. 44, pp. 2537−254 9
- Sheldon P.W., Beg A.C., Fowler J.P. The incidence of lung metastasis in mice after treatment of implanted solid tumors with X-rays or surgery.- Brit. J. Cancer, 1974, v.30, pp. 342−348.
- Shields A.F. Imaging tumor DNA synthesis with C-11-thymidine and positron emission tomography (PET) Abstract.- Cancer Res., 1990, v.31, p.205.
- Shields A.F., Swenson E.R., Bassingthwaighte JB. Contribution of labeled carbon dioxide to PET imaging of C-ll-labeled compounds. J.Nucl.Med., 1992, v.33, pp. 581−586.
- Shields A.F., Kozell LB., Link Jm., et al. Comparison of PET imaging using C-l 1-thymidine labeled in the ring-2 and methyl positions Abstract. -J. Nucl.Med., 1990, v.31, p. 794.
- Shields A.F., Lim K., Grierson J., et al. Utilization of labeled thymidine in DNA synthesis: studies for PET. -J.Nucl.Med., 1990, v.31, pp.337−342.
- Silvestrini R., Daidone M.G., Morta R., Costa A. Predictive of cell kinetics on clinical oumcome of human tumors.- Cell Tissues Kinet., 1984, v. l7,pp.289−294.
- Silvestrini R., Daidone M.G., Valagussa P., et al. 3-H-thymidine labelling index as a prognostic indicator in node positive breast cancer. — J. Clin.Oncol., 1990, N8, pp. 1321−1326.
- Sondak V., Lawrence Т., Ensminger W., Chang A. Preoperative IUDR and radiation for soft tissue sarcomas: preliminary results and normal tissue IUDR incorporation data Abstract. -J. Am.Clin.Oncol., 1990, v.9, A 1228.
- Sotos George A., Grogan Liam and Allegra Carmen J. Preclinical and clinical aspects of biomodulation of 5-fluorouracil. Cancer Treatment Reviews,
- January 1994, v. 20, Issue 1, pp. 11−49.
- Steel G. Growth and survival of tumour stem cells. In: Growth kinetics of tumours. Oxford Clarendon Press, 1977, pp.217−262.
- Strauss L., Dimitrakopoulou A., Clorius J., Schlag P., et al. Fluorine-18-uracil uptake and changes in tumor volume during chemotherapy in patients with hepatic metastases from colorectal cancer (Abstract). -J.Nucl.Med., 1989, v.30, p.911.
- Suit H. Prediction of response of tumors to radiation treatment. In: Abstracts Third Intern. Meeting on Progr. in Radio-Oncol., 1985, Vienna, Austria, p.5.
- Suzanne E. Berry and Timothy J. Kinsella Targeting DNA mismatch repair for radiosensitization. Seminars in Radiation Oncology, October 2001, v. 11, Issue 4, pp.300−315.
- Tagnon H. J. Some considerations on the role of chemotherapy in individualization of cancer therapy. Strahlentherapie, v. 160 (1984), No 11, pp. 681−683
- Teich Natalie, Lowy Douglas R., Hartley Janet W. and Rowe Wallace P.
- Studies of the mechanism of induction of infectious murine leukemia virus from AKR mouse embryo cell lines by 5-iododeoxyuridine and 5-bromodeoxyuridine. -Virology, January 1973, v. 51, Issue 1, pp. 163−173.
- Terada N., Yamamoto R., Takada Т., Taniguchi H., T. Mlyake, Terakawa N., et al. Inhibitory effect of progesterone on cell death of mouse uterine epithelium. -Journal of Steroid Biochemistry, December 1989, v. 33, Issue 6, pp. 1091−1096.
- Terada N., Yamamoto R., Takada Т., Taniguchi H., Terakawa N., et al. Inhibitory effect of androgen on cell death of mouse uterine epithelium. Journal of Steroid Biochemistry, July 1990, v. 36, Issue 4, pp. 305−310.
- Terada N., Yamamoto R., Yamamoto Т., Nishizawa Y., Taniguchi H., et al. Effect of dexamethasone on uterine cell death. The Journal of Steroid Biochemistry and Molecular Biology, January 1991, v. 38, Issue 1, pp. 111−115.
- Thomlinson R.H. Radiation and the vascularity of tumors. Brit.Med.Bull., 1973, v.29,N 1, рр. 29−32.
- Till J.R., Mc Culloch B.A. A direct measurement of .the radiation sensitivity of normal mouse bone marrow cells.- Radiation Res., 1961, v. 14, N2, pp.222−313.
- Tjuvajev J., Muraki A., Ginos J. et al. Iododeoxyuridine uptake and retention as a measure of tumor growth. -J. Nucl. Med., 1993, v.34, pp.1152−1162.
- Tomlinson 1, Rabman N, Frayling I et al. Inherited susceptibility to colorectal adenomas and carcinomas: evidence for a new predisposition gene on 15ql4−22. -Gastroen erotog, 1999, 116, pp.789−795
- Tsurumi Y., Kameyama M., Ishiwata K., et al. Fluorine-18-fluoro-2'-deoxyuridine as a tracer of nucleic acid metabolism in brain tumors.-J. Neurosurg., 1990, v.72,pp.ll0- 113.
- Tubiana M.A. Cell kinetics and radiation oncology.-Int.J. Radi at.Oncol.Biol.Phys., 1982, v.8,pp. 1491−1489
- Tubiana M.A. Gray medal lecture cell kinetics and radiation oncology. -Int.J. Radiation Oncol. Biol. Phys., 1982, v.8, N 9, pp. 1471−1489.
- Tucker D. M., Barnes G. T. and Chakraborty D.P. Semiempirical model for generationg tungsten target x-ray spectra. Med. Phys., 1991, v. 18, pp. 211−218.
- Turner В., Haffty В., Narayanan L. et al. Insulin-like growth factor-1 receptor overexpression mediatescetlular radioresistance and local breast cancer recurrence after lumpectomy and radiation. Cancer Res., 1997, v. 57, pp. 3079−3083.
- Vander Borght Т., Pauwels S., Shambotte L., Beckers C. Repid sinthesis of2C-radiolabelled thymidine: a potential tracer for measurement of liver regeneration by PET (Abstract). -J.Nucl.Med., 1989, v.30, p. 929
- Vanky P., Brockstedt U., Hjerpe A. and Wikstrom B. Kinetic Studies on Epiphyseal Growth Cartilage in the Normal Mouse. -Bone, April 1998, v. 22, Issue 4, pp. 331−339.
- Vaupel P. Hypoxia in neoplastic tissue. Microvascular Res., 1977, v.13, pp. 399 — 408.
- Verhoog L., Brekelmans C., et al. Survival and tumor characteristics of breast cancer patients with gene line mutations of BRCA 1. Lancet 1998, 35, pp. 316 321.
- Washiten W.L., Santi D.V. Assay of intracellular free and macromolecularbound metabolites of 5-fluorodeoxyuridine and 5-fluorouracil. -Cancer Res., 1979, v.39, pp. 3397−3404.
- Watanabe K., Su Т., Klein E., et al. Nucleosides 123 synthesis of antiviral nucleosides: 5-substituted l-(2-deoxy-2-halogeno-b-D-arabinofuranosyl) cytosines and -uracils.Some structure-activity relationshops. J.Med. Chem., 1983, v. 28, pp.152−156.
- Watanabe K., Reichman U., Hirota K., et al. Nucleosides 110 synthesis and antiherpes vims activity of some 2!-fluoro-2'deoxyarabinofuranosylpyrimidine nucleosides. J.Med.Chem., 1979, v.22, pp. 21−24.
- Weichselbaum R., Dahlberg W., Little J.B., et al. Cellular X-ray repair parametere of early passage squemous cell carcinoma lines derived from patients with known responses to radiotherapy. Brit.J.Cancer, 1984, v. 49, pp.595−601.
- Welch A., Jaffe J., Cardoso S. Studies on the pharmacology of 5-iododeoxyuridine in animals and man. Cancer Res., 1960, v.3, p. 161.
- Wen В., Deutsch E., Frascona V. et al. Tyrphostin AG 1024 modulates radiosensitivity in human breast cancer cells. Brit. J. Cancer, 2001, v. 85, pp. 2017
- Wijffels Karien I.E.M., Marres Henri A.M., Peters Johannes P.W., Rijken Paulus F.J.W. Tumour cell proliferation under hypoxic conditions in human head and neck squamous cell carcinomas. Oral Oncology, April 2008, v. 44, Issue 4, pp. 335−344.
- Wjittemore A, Gong G, Itnyre J. Prevalence and contribution of BRCA 1 mutations in breast cancer and ovarian cancer: results from three US population-based case-control studies of ovarian cancer. -Am J. Hum. Genet, 1997, v. 60, pp. 496−504.
- Wood Thomas G., Marongiu Maria Elena and Prusoff William H. Effect of ultraviolet light on DNA structure in 5-iodo-2'-deoxyuridine-substituted HSV-1 DNA. Biochemical Pharmacology, 1 February 1991, v. 41, Issue 3, pp. 439−444.
- Yamane Т., Kitamura Y., Terada N. and Matsumoto K. Proliferative response of seminal vesicle cells to androgen and estrogen in neonatally castrated mice. Journal of Steroid Biochemistry, March 1986, v. 24, Issue 3, pp. 703−708.
- Zucker Marcia L. and Prusoff William IT. Effect of incorporation of 5-iodo-2'-deoxyuridine into HSV-1 DNA on virion sensitivity to ultraviolet light. -Biochemical Pharmacology, 15 October 1987, v. 36, Issue 20, pp. 3471−3476.
- Zucker Marcia L., Mancini William R., Otto Michael J., Lee Jung-Ja Shim and Prusoff William H. Production of herpes simplex virus type 1 thymidine kinase in the presence of thymidine analogues. Antiviral Research, March 1986, v. 6, Issue 2, pp. 69−81.